Key Stats for Johnson & Johnson Stock
- This Week Performance: +2%
- 52-Week Range: $141.5 to $248.9
- Current Price: $248.4
What Happened?
Johnson & Johnson (JNJ) crossed $94.2 billion in sales in 2025, and with $100 billion guidance for 2026, the stock at $248.4 has never been closer to its 52-week high of $248.9.
Driving the momentum, Bloomberg reported on February 19 that J&J is exploring a $20+ billion sale of DePuy Synthes, signaling aggressive portfolio concentration into higher-growth segments.
Powering the re-rating, TREMFYA surged 65.4% in Q4 while CARVYKTI grew 63.2% and DARZALEX crossed $14 billion annually, collectively offsetting STELARA’s 48.6% decline with room to spare.
Beyond the numbers, the market is actively re-rating J&J from a diversified healthcare conglomerate into a focused, high-growth oncology and immunology powerhouse with a clear double-digit growth trajectory ahead.
Chairman and CEO Joaquin Duato stated on the Q4 earnings call that “we have line of sight to double-digit growth by the end of the decade,” contextualizing 28 billion-dollar platforms and $32 billion in R&D and M&A investment in 2025.
Further reinforcing conviction, Blackstone Life Sciences announced a co-funding agreement with J&J on February 23 to jointly finance bleximenib trials, signaling institutional confidence in J&J’s oncology pipeline depth.
Looking ahead, J&J’s $21 billion projected free cash flow, OTTAVA surgical robotics launch, and ICOTYDE approval in 2026 position it to dominate six healthcare segments well into the next decade.
Wall Street’s Take on Johnson & Johnson Stock
J&J’s $20+ billion DePuy Synthes sale exploration directly accelerates its pivot into higher-margin oncology and immunology, confirming the 2026 revenue target of $100 billion.
Fundamentally, revenue grew 6.0% in 2025 to $94.2 billion while normalized EPS jumped 8.1% to $10.79, with 2026 consensus forecasting further acceleration to $11.53.
Currently, 9 analysts rate JNJ a Buy and 5 rate it Outperform, with a mean price target of $232.5, implying 6.4% downside from $248.4, suggesting the stock has outrun near-term consensus.
Notably, the target range spans $155.0 to $265.0, where the high end requires successful ICOTYDE and OTTAVA launches and the low end prices in talc litigation escalation derailing earnings.
What Does the Valuation Model Say?
TIKR’s mid-case model targets $299.6 by December 2030, delivering a 20.6% total return at a 3.9% IRR from today’s $248.4.
The model suggests the stock is approaching fairly valued today, but the DePuy separation unlocks meaningful additional upside.
The market still prices J&J as a slow-growth conglomerate, yet TREMFYA alone grew 65.4% in Q4 and targets $10 billion+ in peak sales.
J&J generated $19.7 billion in free cash flow in 2025 while guiding to $21 billion in 2026, an undeniable compounding engine.
CEO Joaquin Duato’s statement of “line of sight to double-digit growth by end of the decade” signals this is a misunderstood re-rating story.
However, if talc litigation reserves require a significant step-up beyond the $7 billion reversal already booked, the entire 2026 EPS guide of $11.53 faces compression.
Watch the ICOTYDE U.S. psoriasis approval decision, the single regulatory event that confirms J&J’s next blockbuster immunology franchise is real.
JNJ is fairly valued today but transitions to undervalued the moment ICOTYDE launches successfully; watch that approval closely.
Should You Invest in Johnson & Johnson?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up JNJ stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Johnson & Johnson alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze JNJ stock on TIKR for Free →
